Actively Recruiting
Evaluating the Effects of DONQ52 Compared to Placebo on Intestinal Healing and Symptoms in Adults with Active Celiac Disease Following a Gluten-Free Diet
Led by Chugai Pharmaceutical · Updated on 2026-08-14
92
Participants Needed
74
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of DONQ52 on small intestinal damage and celiac-related symptoms in people with active celiac disease who are trying to maintain a gluten-free diet. This Phase II study compares the effects of DONQ52 with a placebo in participants who have ongoing duodenal mucosal damage and persistent symptoms despite following a gluten-free diet. The goal is to see how DONQ52 influences intestinal healing and symptom reduction related to gluten exposure. Participants receive either DONQ52 or a placebo through subcutaneous injections, combined with oral capsules simulating inadvertent gluten exposure SIGE. The study lasts 27 weeks, during which participants maintain their gluten-free diet and follow the protocol for taking the study treatments. Two upper gastrointestinal endoscopies with duodenal biopsies are performed to assess intestinal damage. Throughout the study, participants undergo regular assessments including symptom diaries for gastrointestinal symptoms, blood tests to monitor drug levels and immune responses, and safety evaluations for adverse events. The primary measure is the change in the villous height to crypt depth ratio over 27 weeks, indicating intestinal healing. Additional measurements track symptom changes and immune reactions up to 47 weeks, ensuring long-term monitoring of treatment effects and safety.
CONDITIONS
Brief Title
Study of DONQ52 in Active Celiac Disease
Research Team
C
Clinical trials information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here